Ndibalema Angelamellisy Revelian, Kabuye Deo, Wen Si, Li Lulu, Li Xin, Fan Qiuling
Department of Nephrology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Kairuki Hospital, Dar es Salaam, Tanzania.
Diabetes Metab Syndr Obes. 2020 Jun 12;13:1953-1967. doi: 10.2147/DMSO.S243170. eCollection 2020.
Evidence from both animal and human studies clearly supports the renal beneficial effects of empagliflozin (emp), a sodium glucose co-transporter 2 (SGLT2) inhibitor, but the mechanism in which it exerts its effect is not well understood. In this study, we investigated the capability of emp on reducing hyperglycemia-induced renal proximal tubular epithelial cells injury and we evaluated if the renoprotective effect of emp associates with hypoxia-inducible factor-1α (HIF-1α).
Human kidney cell lines (HK-2 cells) were incubated in normoxia, high glucose with or without emp treatment for 72 hours to evaluate the induction of HIF-1α, glucose transporter-1, SGLT2, the fibrosis signal pathway and epithelial-mesenchymal transition (EMT) markers.
High glucose (HG) increased expression of Collagen IV, Fibronectin, transforming growth factor-beta1 (TGF-β1). However, emp treatment remarkably decreased expression of TGF-β1, accumulation of extracellular matrix proteins (Fibronectin, Collagen IV), as well as (phosphorylated-smad3) P-smad3. HG increased SGLT2 protein expression compared to normal glucose (NG) while emp significantly decreased SGLT2 expression. Furthermore, emp decreased high glucose-induced alpha-smooth muscle actin (α-SMA) expression and reversed epithelial marker (E-catherin) suppression induced by high glucose. In addition, emp treatment for 72 h increased expression of HIF-1α protein (95% CI: -0.5918 to -0.002338, at 100nM, P < 0.05, 95% CI -0.6631 to -0.07367 at 500nM, P < 0.05) in hyperglycemic normoxic HK-2 cells. Furthermore, we observed increased expression of GLUT-1 protein after emp treatment and remarkably decreased cell proliferation.
Emp treatment protected proximal renal tubular cells injury induced by high glucose. Induction of HIF-1α expression by emp may play an essential role in the protection of high glucose-induced proximal renal tubular epithelial cells injury.
动物和人体研究证据均明确支持钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂恩格列净(emp)对肾脏的有益作用,但其作用机制尚不完全清楚。在本研究中,我们探究了恩格列净减轻高血糖诱导的肾近端小管上皮细胞损伤的能力,并评估了其肾脏保护作用是否与缺氧诱导因子-1α(HIF-1α)相关。
将人肾细胞系(HK-2细胞)在常氧、高糖条件下培养72小时,其中部分给予恩格列净处理,以评估HIF-1α、葡萄糖转运蛋白-1、SGLT2、纤维化信号通路及上皮-间质转化(EMT)标志物的诱导情况。
高糖(HG)增加了IV型胶原、纤连蛋白、转化生长因子-β1(TGF-β1)的表达。然而,恩格列净处理显著降低了TGF-β1的表达、细胞外基质蛋白(纤连蛋白、IV型胶原)的积累以及(磷酸化-smad3)P-smad3。与正常葡萄糖(NG)相比,HG增加了SGLT2蛋白表达,而恩格列净显著降低了SGLT2表达。此外,恩格列净降低了高糖诱导的α-平滑肌肌动蛋白(α-SMA)表达,并逆转了高糖诱导的上皮标志物(E-钙黏蛋白)抑制。另外,在高血糖常氧HK-2细胞中,恩格列净处理72小时增加了HIF-1α蛋白表达(100nM时,95%CI:-0.5918至-0.002338,P<0.05;500nM时,95%CI -0.6631至-0.07367,P<0.05)。此外,我们观察到恩格列净处理后GLUT-1蛋白表达增加且细胞增殖显著降低。
恩格列净处理可保护高糖诱导的近端肾小管细胞损伤。恩格列净诱导HIF-1α表达可能在保护高糖诱导的近端肾小管上皮细胞损伤中起重要作用。